更新于：2023-09-06

Clostridium Butyricum (Grand Life Science)

酪酸梭菌活菌 (远大生命科学)

更新于：2023-09-06

概要

概要

基本信息

药物类型

活菌制剂

别名

米桑

靶点-

作用机制

细菌替代物、胃肠道微生物调节剂

治疗领域

其他疾病

在研适应症

急性腹泻

非在研适应症-

原研机构

远大生命科学（重庆）有限公司

在研机构

远大生命科学（重庆）有限公司

非在研机构-

最高研发状态(全球)批准上市

首次获批日期(全球)

中国 (2004-01),

急性腹泻

最高研发状态(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

关联

项与酪酸梭菌活菌 (远大生命科学) 相关的临床试验

NCT05122546 / Active, not recruiting临床1期IIT

Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma

This phase I trial evaluates the effects of CBM588 in combination with standard therapies, nivolumab and cabozantinib, in treating patients with kidney cancer that has spread to other places in the body (advanced/metastatic). The digestive microbiome may have an effect on how patients respond to treatment, and previous research shows that a specific bacteria found in the gut (Bifidobacterium) may predispose participants to a better response to standard therapies. CBM588 is a strain of bacteria that can restore species of Bifidobacterium to the microbiome. The primary aim of this study is to determine how CBM588 changes the microbiome of patients with metastatic renal cell carcinoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving CBM588, nivolumab, and cabozantinib may kill more tumor cells.

开始日期2021-11-01

申办/合作机构

City of Hope National Medical Center

[+1]

NCT04688242 / Recruiting临床2期IIT

A Randomized, Phase 2 Study of Anal Dilatation Plus Probiotics Before Ileostomy Reduction for Low Anterior Resection Syndrome After Sphincter-preserving Proctectomy

This is randomized, phase 2 trial in patients with rectal cancer undergoing sphincter-preserving proctectomy and temporary ileostomy, to explore the effects of anal dilatation plus probiotics administered per anus before ileostomy reduction in relieving postoperative bowel dysfunction known as low anterior resection syndrome (LARS).

开始日期2021-02-20

申办/合作机构

中山大学附属第六医院

[+1]

NCT03829111 / Active, not recruiting临床1期IIT

Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Metastatic Renal Cell Carcinoma

This phase I trial studies how well CBM588 works when given together with nivolumab and ipilimumab in treating patients with kidney cancer that is stage IV or has spread to other places in the body (advanced). CBM588 is a probiotic that may help to increase the effect of immunotherapy. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CBM588, nivolumab, and ipilimumab may work better in treating patients with kidney cancer.

开始日期2019-05-14

申办/合作机构

City of Hope National Medical Center

[+1]

100 项与酪酸梭菌活菌 (远大生命科学) 相关的专利（医药）

登录后查看更多信息

295

项与酪酸梭菌活菌 (远大生命科学) 相关的文献（医药）

2023-07-31·Microbiology spectrum

Identification and Characterization of a Potential Probiotic, Clostridium butyricum G13, Isolated from the Intestine of the Mud Crab (Scylla paramamosain).

Article

作者: Huifen Liang ; Ngoc Tuan Tran ; Tiaoqiu Deng ; Jinkun Li ; Yifan Lei ; Mohammad Akibul Hasan Bakky ; Ming Zhang ; Rui Li ; Wenxuan Chen ; Yueling Zhang ; Xiuli Chen ; Shengkang Li

The butyrate-producing bacterium Clostridium butyricum has been proven to be important in improving the growth and health benefits of aquatic animals. In this study, C. butyricum G13 was isolated for the first time from the gut of the mud crab (Scylla paramamosain). The results of this study showed that C. butyricum G13 could produce a high concentration of butyric acid and grow well in a wide range of pHs (4 to 9) and NaCl (1 to 2.5%) and bile salt (0.2 to 1.0%) concentrations. In vitro characterization revealed that C. butyricum G13 is a Gram-positive and gamma-hemolytic bacterium sensitive to most antibiotics and shows hydrophobicity and the capacity to degrade starch. In vitro fermentation using mud crab gut contents showed that C. butyricum G13 alone or in combination with galactooligosaccharides (GOS) and/or resistant starch (RS) significantly increased butyric acid production and beneficially affected the abundance and diversity of intestinal microbiota. In addition, C. butyricum G13 can improve the survival rate of mud crabs and effectively maintain the normal structure of gut morphology after infection with Vibrio parahaemolyticus. In conclusion, C. butyricum G13 can be considered a potential probiotic that improves the immune capacity and confers health benefits on mud crabs. IMPORTANCE With the development of society, more and more aquatic animals are demanded. Intensification in the aquaculture scale is facing problems, such as disease outbreaks, eutrophication of water bodies, and misuse of antibiotics. Among these challenges, disease outbreak is the most important factor directly affecting aquaculture production. It is crucial to explore new approaches effective for the prevention and control of diseases. Probiotics have been widely used in aquaculture and have shown beneficial effects on the host. In this study, the butyrate-producing bacterium Clostridium butyricum G13 was isolated for the first time from the intestine of the mud crab through in vitro fermentation. The bacterium has probiotic properties and changes the gut microbiota to be beneficial to hosts in vitro as well as protecting hosts from Vibrio parahaemolyticus infection in vivo. The outcomes of this study indicate that C. butyricum G13 can be used as a potential probiotic in mud crab aquaculture.

2023-07-30·Phytotherapy research : PTR

Therapeutic effect of Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. leaves on ischemic stroke via the microbiota-gut-brain axis.

Article

作者: Rongjin Wang ; Yuzhen Sun ; Meiyuan Wang ; Hanlin Li ; Shu Liu ; Zhongying Liu

Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. leaves (ESL) are widely used to treat ischemic stroke (IS); however, the specific mechanism remains unclear. The microbiota-gut-brain axis plays a critical role in IS and has become a potential therapeutic target. This study aimed to reveal and verify the therapeutic effect of ESL on IS through the microbiota-gut-brain axis. Ultra-high-performance liquid chromatography coupled with mass spectrometry-based untargeted/targeted metabolomics combined with 16S rRNA microbiota sequencing strategy were used to investigate the regulatory effect of ESL on the metabolism and intestinal microenvironment after IS. Lactobacillus reuteri and Clostridium butyricum were used to treat rats with IS to verify that elevated levels of probiotics are key factors in the therapeutic effect of ESL. The results showed that IS significantly altered the accumulation of 41 biomarkers, while ESL restored their concentrations back to normal. Moreover, ESL alleviated the dysbiosis of gut microbiota brought on by IS, by reducing the abundance of pathogens and increasing the abundance of probiotics (e.g., Lactobacillus reuteri and Clostridium butyricum); this could reduce post-stroke injury, thereby having a certain protective effect on IS. This study reveals that ESL plays an important role in treating IS through the microbiota-gut-brain axis, maintaining metabolic homeostasis in vivo.

2023-06-22·Journal of applied microbiology

Diversity within the species Clostridium butyricum: pan-genome, phylogeny, prophage, carbohydrate utilization, and antibiotic resistance.

Article

作者: Zhangming Pei ; Yufei Liu ; Zhi Yi ; Jingyi Liao ; Hongchao Wang ; Hao Zhang ; Wei Chen ; Wenwei Lu

AIMS:

Clostridium butyricum has been recognized as a strong candidate for the "next generation of probiotics" due to its beneficial roles on humans. Owing to our current understanding of this species is limited, it is imperative to unveil the genetic variety and biological properties of C. butyricum on sufficient strains.

METHODS AND RESULTS:

We isolated 53 C. butyricum strains and collected 25 publicly available genomes to comprehensively assess the genomic and phenotypic diversity of this species. Average nucleotide identity and phylogeny suggested that multiple C. butyricum strains might share the same niche. C. butyricum genomes were replete with prophage elements, but the CRISPR-positive strain efficiently inhibited prophage integration. C. butyricum utilizes cellulose, alginate, and soluble starch universally, and shows general resistance to aminoglycoside antibiotics.

CONCLUSIONS:

C. butyricum exhibited a broad genetic diversity from the extraordinarily open pan-genome, extremely convergent core genome, and ubiquitous prophages. In carbohydrate utilization and antibiotic resistance, partial genotypes have a certain guiding significance for phenotypes.

项与酪酸梭菌活菌 (远大生命科学) 相关的新闻（医药）

2023-07-22

·生物探索

男性更易患结直肠癌的潜在机理

研究发现，女性结直肠癌(CRC)患者的麦芽香肉杆菌(Carnobacterium maltaromatium )特异性减少。然而，麦芽香肉杆菌如何影响结直肠癌的发展仍然知之甚少。2023年7月20日，香港中文大学于君、胡嘉麒（William Ka Kei Wu）及Matthew Tak Vai Chan共同通讯在Cancer Cell 在线发表了题为“Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice”的研究论文，该研究发现在两种小鼠CRC模型中，给予麦芽香肉杆菌能以雌性特异性的方式减少肠道肿瘤的形成。研究结果显示雌激素通过增加与该细菌的DD-CPase结合的SLC3A2的结肠表达，增加了麦芽香肉杆菌的附着和定植。代谢组学和转录组学分析揭示了麦芽香肉杆菌灌胃小鼠肠道中维生素D相关代谢物丰度的增加和维生素D受体(VDR)信号的粘膜激活以肠道微生物组和VDR依赖的方式。总之，麦芽香肉杆菌以雌激素依赖的方式定植肠道，并与其他微生物一起增加肠道维生素D的产生，激活宿主VDR以抑制结直肠癌。另外，2023年7月15日，香港中文大学于君团队在Journal of Hepatology （IF=26）在线发表题为“Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts anti-tumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis 2”的研究论文，该研究探讨了YTHDF1在NASH-HCC中的功能作用、分子机制及其与肿瘤免疫微环境的相互作用。该研究发现YTHDF1通过EZH2-IL-6信号传导促进NASH-HCC的肿瘤发生，其招募和激活MDSCs导致细胞毒性CD8+ T细胞功能障碍。YTHDF1可能是提高NASH-HCC抗PD-1免疫治疗应答的新靶点。2023年7月15日，香港中文大学于君团队在Journal of Hepatology （IF=26）在线发表题为“Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma”的研究论文，该研究表明假长双歧杆菌产生的乙酸盐抑制非酒精性脂肪肝疾病相关的肝细胞癌。该研究表明假长双歧杆菌通过肠-肝轴分泌抗肿瘤代谢物乙酸盐，对NAFLD-HCC具有保护作用。假长双歧杆菌是预防NAFLD- 2型HCC的潜在益生菌。2023年6月29日，香港中文大学于君团队在Nature Microbiology（IF=28）在线发表题为“Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid”的研究论文，该研究发现可溶性纤维菊粉（inulin）被发现比不溶性纤维素更有效地抑制小鼠NASH进展，如肝脏脂肪变性、坏死炎症、球囊和纤维化的减少。该研究采用稳定同位素探测追踪在NASH进展过程中13C-菊粉在肠道细菌基因组和代谢物中的掺入。该研究发现狄氏副拟杆菌（Parabacteroides distasonis ）富含13C-菊粉。13C-菊粉宏基因组和代谢组的整合表明，狄氏副拟杆菌利用菊粉产生了十五烷酸，一种奇链脂肪酸，这在体外和无菌小鼠中得到了证实。狄氏副拟杆菌或十五烷酸对小鼠NASH有保护作用。在机制上，菊粉、狄氏副拟杆菌或十五烷酸可以恢复NASH模型中的肠道屏障功能，从而降低血清脂多糖和肝脏促炎细胞因子的表达。总的来说，这表明肠道菌群成员可以利用膳食纤维产生有益的代谢物来抑制代谢性疾病。2023年5月9日，香港中文大学于君团队在Gastroenterology 在线发表了题为“ALKBH5 Drives Immune Suppression via targeting AXIN2 to Promote Colorectal Cancer and is a Target for Boosting Immunotherapy”的研究论文，该研究揭示了AlkB同源物5 (ALKBH5)，一种RNA N6 -甲基腺苷(m6A ) 去甲基化酶，能驱动免疫抑制，是促进结直肠癌ICB治疗的分子靶点。该研究在CRC中发现了ALKBH5-m6A-AXIN2-Wnt-DKK1轴，该轴驱动免疫抑制以促进肿瘤发生。研究结果表明，靶向ALKBH5是一种很有前途的策略，能使CRC对免疫治疗重新敏感。2023年3月22日，香港中文大学于君及北京大学季加孚共同通讯在Cell Reports 在线发表题为“The N6-methyladenine DNA demethylase ALKBH1 promotes gastric carcinogenesis by disrupting NRF1 binding capacity”的研究论文，该研究发现胃癌(GC)细胞和肿瘤与正常的胃组织和细胞相比，6mA水平明显降低。6mA在周围的转录起始位点大量存在，并出现在共识基序上。在6mA调节因子中，与邻近正常组织相比，去甲基化酶ALKBH1在GC组织中显著过表达。此外，ALKBH1的高表达与GC患者的低生存率相关。敲除小鼠ALKBH1可损害化学诱导的胃癌发生。机制上，ALKBH1通过介导DNA 6mA去甲基化来抑制基因表达。特别是，6mA位点在NRF1结合序列中富集，并被ALKBH1靶向去甲基化。ALKBH1诱导的6mA去甲基化抑制NRF1驱动的下游靶标转录，包括参与AMP活化蛋白激酶(AMPK)信号通路的多个基因。因此，ALKBH1抑制AMPK信号，导致代谢向Warburg效应转变，促进肿瘤发生。2023年1月30日，香港中文大学于君团队在Gut 杂志在线发表题为“Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer”的研究论文，该研究通过整合MeRIP-seq、RNA-seq和Ribo-seq发现p65/Rela是YTHDF1的靶点。YTHDF1促进p65转译上调CXCL1，增加MDSC通过CXCL1- cxcr2轴的迁移。增加的MSDCs在TIME中拮抗功能性CD8+ T细胞。重要的是，通过CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)或VNPs-siYTHDF1靶向YTHDF1增强了MSI-H CRC中的抗PD1疗效，并克服了MSS CRC中的抗PD1耐药性。总之，该研究表明YTHDF1通过m6A-p65-CXCL1/CXCR2轴抑制抗肿瘤免疫，促进CRC，是免疫检查点阻断治疗的治疗靶点。结直肠癌(CRC)是一种常见且致命的恶性肿瘤。消耗CRC的细菌作为益生菌和/或其代谢物可能会产生一个不允许CRC发展的肠道微环境。特别是，由于其天然来源，这些制剂具有相对较高的安全性。最近的一项临床研究表明，双歧杆菌和乳杆菌可降低结直肠癌术后患者的促炎细胞因子水平。该研究发现两种在CRC缺失的细菌，即嗜热链球菌和鸡乳杆菌，分别通过分泌β-半乳糖苷酶和吲哚-3乳酸来阻止小鼠肠道肿瘤的发生。此外，益生菌分泌的抑瘤代谢物可以发挥直接的抗癌作用。为了开发益生菌作为预防结直肠癌的策略，鉴定其他耗尽CRC的细菌是关键。男性患结直肠癌的风险高于女性。在这方面，肠道微生物群的性别特异性差异可能是人类疾病中观察到的性别差异的基础。然而，肠道菌群如何影响结直肠癌的发展仍然知之甚少。值得注意的是，性激素对肠道微生物群的影响和对同一微生物群落的性别特异性反应都有报道。人类研究也报告了男性肠道微生物群的变化更大，性别特异性微生物相互作用对慢性疲劳综合征的症状表现有很强的影响。因此，肠道组织直接暴露于肠道微生物要求在设计基于益生菌的干预措施时考虑肠道微生物群的性别特异性差异。文章模式图（图源自Cancer Cell ）该研究通过对结直肠癌患者和健康对照者的多队列粪便样本进行鸟枪宏基因组测序，确定了5种候选益生菌 (S. thermophilus, L. gallinarum, Carnobacterium maltaromaticum, Clostridium butyricum, and Streptococcus salivarius )在结直肠癌中消失。然而，麦芽香肉杆菌的抗结直肠癌作用尚不清楚。麦芽香肉杆菌最初是作为乳酸菌从牛奶中分离出来的，后来被用于生产即食肉类。由于其强大的细菌素生产能力，麦芽香肉杆菌对鱼类和肉类产品中的致病菌(如单核细胞增生李斯特菌)具有保护作用。该研究发现麦芽香肉杆菌在结直肠癌患者的粪便样本中以性别特异性的方式显著减少。该研究在此展示了麦芽香肉杆菌的性别特异性CRC抑制作用。该研究进一步发现了麦芽香肉杆菌促进肠道维生素D的产生，从而激活结肠粘膜维生素D受体(VDR)信号。因此，该研究结果表明，性别特异性微生物可以调节性别差异的结直肠癌进展。文章来源“iNature”责编|文竞择校对|文竞择End 往期精选围观历史性突破！不需卵子和精子就可以合成人类胚胎热文富豪用儿子血浆“回春”科学吗？Science：血液牛磺酸缺乏驱动衰老热文世界首例！35岁的她，通过机器人操刀移植的子宫，成功诞下宝宝热文‍为了避免心脏骤停，53岁的他成为“第一个”植入开创性除颤器的心脏病患者热文首次披露！175家生物制药公司的薪资数据：薪资中位数达20万美元点击“阅读原文”，了解更多~

微生物疗法临床研究

研发状态

适应症	最高研发状态	国家/地区	公司
急性腹泻	批准上市	中国更多	远大生命科学（重庆）有限公司更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EHA2023 AI 标引	-	造血干细胞移植	38	CLOSTRIDIUM BUTYRICUM MIYAIRI 588	餘積窪網窪製壓獵齋願 = 襯膚鹽獵餘艱膚願築壓糧範願鏇網獵遞鏇艱網 (夢觸淵範繭觸憲獵憲顧 )	-	2023-06-08